Market Research Logo

Heptares Therapeutics Limited - Product Pipeline Review - 2016

Heptares Therapeutics Limited - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Heptares Therapeutics Limited - Product Pipeline Review - 2016’, provides an overview of the Heptares Therapeutics Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Heptares Therapeutics Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Heptares Therapeutics Limited
The report provides overview of Heptares Therapeutics Limited including its business description, key facts, and locations and subsidiaries
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report assesses Heptares Therapeutics Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report features Heptares Therapeutics Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Heptares Therapeutics Limited’s strategic position with total access to detailed information on its product pipeline
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Heptares Therapeutics Limited
Identify potential new clients or partners in the target demographic
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Heptares Therapeutics Limited’s pipeline depth and focus of pipeline therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Table of Contents
List of Tables
List of Figures
Heptares Therapeutics Limited Snapshot
Heptares Therapeutics Limited Overview
Key Information
Key Facts
Heptares Therapeutics Limited - Research and Development Overview
Key Therapeutic Areas
Heptares Therapeutics Limited - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Heptares Therapeutics Limited - Pipeline Products Glance
Heptares Therapeutics Limited - Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Heptares Therapeutics Limited - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Heptares Therapeutics Limited - Drug Profiles
HTL-9936
Product Description
Mechanism of Action
R&D Progress
Drug to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases
Product Description
Mechanism of Action
R&D Progress
Drug to Agonize Muscarinic M4 Receptors for Psychiatric Diseases and Alzheimer's Disease
Product Description
Mechanism of Action
R&D Progress
HTL-1071
Product Description
Mechanism of Action
R&D Progress
HTL-14242
Product Description
Mechanism of Action
R&D Progress
HTL-6641
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Agonize GLP-1 Receptor for Type 2 Diabetes
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Agonize GPR39 for Type 1 and Type 2 Diabetes
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Antagonize GPCR for Inflammation
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Target GPCR for Undisclosed Indications
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize CXCR4 for Cancer and HIV
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Target GPCR for CNS Disorders
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Target mGluR2 for Schizophrenia
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Target GPCR for Pain, Cardiovascular, Metabolic and Inflammatory Disorders
Product Description
Mechanism of Action
R&D Progress
Heptares Therapeutics Limited - Pipeline Analysis
Heptares Therapeutics Limited - Pipeline Products by Target
Heptares Therapeutics Limited - Pipeline Products by Route of Administration
Heptares Therapeutics Limited - Pipeline Products by Molecule Type
Heptares Therapeutics Limited - Pipeline Products by Mechanism of Action
Heptares Therapeutics Limited - Recent Pipeline Updates
Heptares Therapeutics Limited - Dormant Projects
Heptares Therapeutics Limited - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Heptares Therapeutics Limited, Key Information
Heptares Therapeutics Limited, Key Facts
Heptares Therapeutics Limited - Pipeline by Indication, 2016
Heptares Therapeutics Limited - Pipeline by Stage of Development, 2016
Heptares Therapeutics Limited - Monotherapy Products in Pipeline, 2016
Heptares Therapeutics Limited - Out-Licensed Products in Pipeline, 2016
Heptares Therapeutics Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016
Heptares Therapeutics Limited - Phase I, 2016
Heptares Therapeutics Limited - Preclinical, 2016
Heptares Therapeutics Limited - Discovery, 2016
Heptares Therapeutics Limited - Pipeline by Target, 2016
Heptares Therapeutics Limited - Pipeline by Route of Administration, 2016
Heptares Therapeutics Limited - Pipeline by Molecule Type, 2016
Heptares Therapeutics Limited - Pipeline Products by Mechanism of Action, 2016
Heptares Therapeutics Limited - Recent Pipeline Updates, 2016
Heptares Therapeutics Limited - Dormant Developmental Projects,2016
List of Figures
Heptares Therapeutics Limited - Pipeline by Top 10 Indication, 2016
Heptares Therapeutics Limited - Pipeline by Stage of Development, 2016
Heptares Therapeutics Limited - Monotherapy Products in Pipeline, 2016
Heptares Therapeutics Limited - Out-Licensed Products in Pipeline, 2016
Heptares Therapeutics Limited - Pipeline by Top 10 Target, 2016
Heptares Therapeutics Limited - Pipeline by Route of Administration, 2016
Heptares Therapeutics Limited - Pipeline by Molecule Type, 2016
Heptares Therapeutics Limited - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report